BioSpace News Archive

MedTrust Medical Transport, a MedTrust Holdings company and a premier provider of ambulance services in the Lowcountry and Pee Dee regions of South Carolina, has been named to the 2018 Inc. 5000, confirming its position among the fastest-growing companies in America.

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced it is now accepting submissions of original visual and written artistic content from teens impacted by amyotrophic lateral sclerosis (ALS)

Vizient announces its support for the approval of UDENYCA™ (pegfilgrastim-cbqv), the second pegfilgrastim biosimilar approved by the Food and Drug Administration (FDA) and the first to be authorized by both the U.S. and the European Commission for patients with cancer receiving myelosuppressive chemotherapy.

On October 11, in conjunction with Hospice of Marion County’s “Uptown Hoedown” Gala and fundraiser, Florida Hospice & Palliative Care Association presented Rep. Charlie Stone (R), Ocala, with a “2018 Hospice Champion Award.”

“I conceived of this invention due to the amount of time I have spent in hospitals,” said an inventor from Euless, Texas. “This inspired me to develop a better bedside table that could make life easier for patients as well as nurses.”

CRO recognized for its dynamic, company-wide growth in 2018.

The Washington State Veterinary Medical Association (WSVMA) held the Pacific Northwest Veterinary Conference in Tacoma, Wash., Sept. 28 – Sept. 30. Veterinarians, veterinary staff, and citizens were honored at WSVMA’s award ceremonies on Friday, Sept. 28.

Time, flexibility and engagement are the keys to successfully implementing patient safety initiatives at scale, according to new recommendations published today for policy makers at the hospital, hospital association, state and national levels.

Genetics can be used to predict a patient’s response to antipsychotic drug treatment for schizophrenia, according to a recent study by investigators at The Feinstein Institute for Medical Research.

Robust biological target engagement in patient tumor cells confirms the activity of AsiDNA™ when administered intravenously